Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRD8B8)

Drug Name
NSI-189 Drug Info
Synonyms
NSI-189; 1270138-40-3; (4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone; UNII-YVE9U408ZL; YVE9U408ZL; NSI 189; (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone; Methanone, (2-((3-methylbutyl)amino)-3-pyridinyl)(4-(phenylmethyl)-1-piperazinyl)-; Methanone, [2-[(3-methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]-; NSI189; SCHEMBL9999791; EX-A277; MolPort-028-747-097; NS189; BCP08748; AOB87795; ZINC98023167; AKOS025395148; CS-2029; SB17520; NCGC00371142-05; DA-46482; AK199356
Cross-matching ID
PubChem CID
50922681
CAS Number
CAS 1270138-40-3
TTD Drug ID
D06VHG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Citrate cycle (TCA cycle) 2.21 0.00e+0 30/30 (100%) DLD;PCK1;ACLY;...
Glycolysis / Gluconeogenesis 2.08 0.00e+0 56/67 (83.58%) PGAM1;DLD;TPI1;...
Pyruvate metabolism 1.95 7.65e-3 41/47 (87.23%) DLD;PKM;PCK1;...
Propanoate metabolism 1.80 2.68e-2 30/34 (88.24%) DLD;ACAT2;ACAT1;...
Steroid biosynthesis 1.78 2.60e-2 19/20 (95%) SC5D;DHCR7;DHCR24;...
mRNA surveillance pathway 1.74 3.32e-2 71/98 (72.45%) PPP2R1B;GSPT2;EIF4A3;...
NOD-like receptor signaling pathway -1.62 4.20e-2 145/181 (80.11%) RIPK1;TRPV2;TNF;...
Platelet activation -1.63 4.22e-2 106/124 (85.48%) GNAQ;PLA2G4A;MAPK3;...
GABAergic synapse -1.69 2.57e-2 76/89 (85.39%) CACNA1D;GNB5;SLC38A1;...
Cytokine-cytokine receptor interaction -1.71 2.11e-2 246/295 (83.39%) IL37;CCR7;LTBR;...
Coronavirus disease -1.72 2.09e-2 215/232 (92.67%) C8G;JUN;RPS16;...
Natural killer cell mediated cytotoxicity -1.72 2.18e-2 99/131 (75.57%) IFNGR2;RAF1;SHC3;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.72 2.17e-2 79/89 (88.76%) NFATC1;JUN;PPP3CA;...
Epstein-Barr virus infection -1.75 1.60e-2 189/202 (93.56%) PSMD3;RAC1;HLA-DOA;...
Cytosolic DNA-sensing pathway -1.76 1.45e-2 52/63 (82.54%) IL18;IL1B;PYCARD;...
Measles -1.76 1.52e-2 133/139 (95.68%) CCND1;IFNAR2;NFKBIB;...
NF-kappa B signaling pathway -1.77 1.60e-2 90/104 (86.54%) TRAF1;EDAR;TRAF5;...
Hematopoietic cell lineage -1.78 1.56e-2 90/99 (90.91%) CD38;ANPEP;IL9R;...
Chemokine signaling pathway -1.78 1.65e-2 163/192 (84.9%) PXN;CCL13;GNAQ;...
Viral protein interaction with cytokine and cytokine re... -1.79 1.67e-2 84/100 (84%) IL37;CCR7;LTBR;...
Influenza A -1.85 8.93e-3 156/172 (90.7%) MAPK3;MAPK1;CREBBP;...
B cell receptor signaling pathway -1.86 9.56e-3 71/81 (87.65%) NFATC1;JUN;PPP3CA;...
Autoimmune thyroid disease -1.87 1.03e-2 46/53 (86.79%) HLA-F;HLA-C;HLA-DOA;...
Inflammatory bowel disease -1.87 1.12e-2 58/65 (89.23%) IL18RAP;TNF;STAT4;...
Asthma -1.87 1.22e-2 25/31 (80.65%) CCL11;TNF;IL13;...
Intestinal immune network for IgA production -1.88 9.74e-3 38/48 (79.17%) CCL25;HLA-DOA;HLA-DOB;...
T cell receptor signaling pathway -1.93 5.41e-3 93/104 (89.42%) IFNG;PAK2;CBLB;...
Viral myocarditis -1.96 1.52e-3 53/60 (88.33%) HLA-F;HLA-C;SGCG;...
Th17 cell differentiation -2.02 0.00e+0 95/107 (88.79%) NFATC1;JUN;PPP3CA;...
C-type lectin receptor signaling pathway -2.03 0.00e+0 93/104 (89.42%) PTPN11;MRAS;CALML5;...
Allograft rejection -2.06 0.00e+0 32/38 (84.21%) IFNG;HLA-F;TNF;...
Th1 and Th2 cell differentiation -2.14 0.00e+0 80/92 (86.96%) IFNG;STAT5A;IL2RA;...
Type I diabetes mellitus -2.17 0.00e+0 38/43 (88.37%) IFNG;HLA-F;TNF;...
Graft-versus-host disease -2.29 0.00e+0 32/42 (76.19%) IFNG;HLA-F;TNF;...
Primary immunodeficiency -2.38 0.00e+0 33/38 (86.84%) IL2RG;RFXANK;CD40LG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H